Oruka Therapeutics appoints Laura Sandler as COO, effective July 1, 2025

Oruka Therapeutics, Inc.

Base salary of $460,000 per year; eligible for annual bonus targeted at 40% of base.
Granted option to purchase 25,000 shares of common stock; vests 25% on first anniversary, then monthly over 36 months.
Severance: 12 months base salary if terminated without cause or for good reason outside change-in-control period.
Within change-in-control period: severance of 1x base salary plus target bonus, plus full equity acceleration.
Sandler previously served as SVP of Operations at Oruka since March 2024.

item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.